What Is AI Drug Discovery?
AI drug discovery is the use of computational models to make parts of therapy development more searchable and testable. Models may help researchers identify disease targets, predict protein structure or function, design molecules, interpret variants, mine scientific literature, or decide which experiment should happen next. The strongest systems are increasingly connected to real lab data rather than relying only on digital predictions.
Plain-English explanation
AI drug discovery is the use of computational models to make parts of therapy development more searchable and testable. Models may help researchers identify disease targets, predict protein structure or function, design molecules, interpret variants, mine scientific literature, or decide which experiment should happen next. The strongest systems are increasingly connected to real lab data rather than relying only on digital predictions.
Why it matters
Rare disease research often has limited time, limited funding, and limited data. AI will not remove the need for experiments, but it may help researchers make better choices about which ideas deserve those experiments. That could matter deeply for foundations and families trying to move a field forward with scarce resources.
How it works
Researchers train or use models on biological, chemical, genetic, clinical, or literature data. The model generates predictions or ranked options, such as a likely target or molecule. Scientists then test those predictions in assays, cells, animal models, or clinical studies. The most useful loop is iterative: model, test, learn, redesign, and test again.
Key terms
Related interviews and articles
Dr. Guoping Feng (MIT) on SHANK3 Gene Therapy, Brain Disorders, and What’s Coming Next
Dr. Guoping Feng
Welcome — I’m Ron Kleiman, and this is GENEration Hope. In this episode, I’m joined by Dr. Guoping Feng, Professor of Neuroscience at MIT, affiliated with the McGovern Institute, the Yang Tan Collective, and the Broad Institute. 
What AI Drug Discovery Could Mean for Rare Disease Families
AI drug discovery is entering a new phase: not just better software, but a new industrial stack linking frontier models, pharma data, robotics, and real experiments.
Why it matters: Rare disease research often starts with small datasets, limited funding, urgent timelines, and difficult trial design. AI-linked discovery systems could help researchers generate stronger candidates and better experiments faster, but families should watch for clinical validation, access, manufacturing, and clear evidence rather than hype.
Source: GENEration Hope editorial analysis